Last reviewed · How we verify
Esomeprazole Na
Esomeprazole Na is a Proton pump inhibitor (PPI) Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome. Also known as: Nexium.
Esomeprazole sodium inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach.
Esomeprazole sodium is used to prevent rebleeding after successful endoscopic therapy of a bleeding peptic ulcer and to treat conditions such as esophagitis and reflux. It is a medication that works by inhibiting the H+/K+ ATPase enzyme, which is involved in the production of stomach acid.
At a glance
| Generic name | Esomeprazole Na |
|---|---|
| Also known as | Nexium |
| Sponsor | AstraZeneca |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole that irreversibly inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, reducing intragastric acidity. The sodium salt formulation allows for rapid intravenous administration, making it suitable for acute acid-related conditions where oral therapy is not feasible.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of gastric ulcers in patients receiving NSAIDs
- Acute erosive esophagitis
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Hypomagnesemia
Key clinical trials
- High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer (PHASE3)
- Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esomeprazole Na CI brief — competitive landscape report
- Esomeprazole Na updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Esomeprazole Na
What is Esomeprazole Na?
How does Esomeprazole Na work?
What is Esomeprazole Na used for?
Who makes Esomeprazole Na?
Is Esomeprazole Na also known as anything else?
What drug class is Esomeprazole Na in?
What development phase is Esomeprazole Na in?
What are the side effects of Esomeprazole Na?
What does Esomeprazole Na target?
Related
- Drug class: All Proton pump inhibitor (PPI) drugs
- Target: All drugs targeting H+/K+-ATPase (proton pump)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Peptic ulcer disease
- Indication: Drugs for Zollinger-Ellison syndrome
- Also known as: Nexium
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing